Latest News about IPSEF
Recent news which mentions IPSEF
From Benzinga
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
August 21, 2023
From Benzinga
From Benzinga
France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline
January 09, 2023
From Benzinga
Why Merrimack Shares Are Surging Over 200% Today?
November 09, 2022
From Benzinga
From Benzinga
Why Is Epizyme (EPZM) Stock Up 75% Today?
June 27, 2022
From InvestorPlace
Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why
June 27, 2022
From Benzinga
Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer
May 03, 2022
From Benzinga
EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer
March 25, 2022
From Benzinga
From Benzinga
Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful
December 17, 2021
From Benzinga
Ipsen Stock Declines After Pulling Rare Disease Application
August 13, 2021
From Benzinga
Exicure Stock Surges On Over $1B Option Licensing Pact With Ipsen For Rare Neurodegenerative Disorders
August 02, 2021
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.